Outcomes of long-term responders to anti-programmed death 1 and anti-programmed death ligand 1 when being rechallenged with the same anti-programmed death 1 and anti-programmed death ligand 1 at progression

Bernard-Tessier A.; Baldini C.; Martin Patricia; Champiat Stephane; Hollebecque Antoine; Postel-Vinay Sophie; Varga Andrea; Bahleda Rastilav; Gazzah Anas; Michot Jean-Marie; Ribrag Vincent; Armand Jean-Pierre; Marabelle Aurelien; Soria Jean-Charles; Massard C.

首页> 外文期刊>European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) >Outcomes of long-term responders to anti-programmed death 1 and anti-programmed death ligand 1 when being rechallenged with the same anti-programmed death 1 and anti-programmed death ligand 1 at progression

【24h】

Outcomes of long-term responders to anti-programmed death 1 and anti-programmed death ligand 1 when being rechallenged with the same anti-programmed death 1 and anti-programmed death ligand 1 at progression

机译：长期响应者的结果对反编程死亡1和反编程死亡配体1在进展中与相同的反编程死亡1和反编程死亡配体1进行重新启动时

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background: Long-term responders have been observed with anti-programmed death 1 and anti-programmed death ligand 1 (anti-PD(L)1). Optimal duration of therapy in responding and stable disease (SD) patients is unclear with various attitudes encompassing treatment until progression disease, stopping therapy after a defined timeframe.

机译：背景：使用反编程死亡1和反编程死亡配体1（抗PD（L）1）观察到长期响应者。响应和稳定疾病（SD）患者的最佳治疗持续时间尚不清楚包含治疗的各种态度，直至渐进疾病，在定义的时间范围内停止治疗。

著录项

来源
《European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)》 |2018年第2018期|共5页
作者
Bernard-Tessier A.; Baldini C.; Martin Patricia; Champiat Stephane; Hollebecque Antoine; Postel-Vinay Sophie; Varga Andrea; Bahleda Rastilav; Gazzah Anas; Michot Jean-Marie; Ribrag Vincent; Armand Jean-Pierre; Marabelle Aurelien; Soria Jean-Charles; Massard C.;
展开▼
作者单位

Univ Paris Saclay F-94805 Villejuif France;

Univ Paris Saclay Drug Dev Dept DITEP Gustave Roussy F-94805 Villejuif France;

Univ Paris Saclay Drug Dev Dept DITEP Gustave Roussy F-94805 Villejuif France;

Univ Paris Saclay Drug Dev Dept DITEP Gustave Roussy F-94805 Villejuif France;

Univ Paris Saclay Drug Dev Dept DITEP Gustave Roussy F-94805 Villejuif France;

Univ Paris Saclay Drug Dev Dept DITEP Gustave Roussy F-94805 Villejuif France;

Univ Paris Saclay Drug Dev Dept DITEP Gustave Roussy F-94805 Villejuif France;

Univ Paris Saclay Drug Dev Dept DITEP Gustave Roussy F-94805 Villejuif France;

Univ Paris Saclay Drug Dev Dept DITEP Gustave Roussy F-94805 Villejuif France;

Univ Paris Saclay Drug Dev Dept DITEP Gustave Roussy F-94805 Villejuif France;

Univ Paris Saclay Drug Dev Dept DITEP Gustave Roussy F-94805 Villejuif France;

Univ Paris Saclay Drug Dev Dept DITEP Gustave Roussy F-94805 Villejuif France;

Univ Paris Saclay Drug Dev Dept DITEP Gustave Roussy F-94805 Villejuif France;

Univ Paris Saclay Drug Dev Dept DITEP Gustave Roussy F-94805 Villejuif France;

Univ Paris Saclay Drug Dev Dept DITEP Gustave Roussy F-94805 Villejuif France;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词
Immunotherapy; Programmed cell death 1 receptor; Programmed cell death 1 ligand; Reinduction; Long-term follow-up;

机译：免疫疗法;编程的细胞死亡1受体;编程的细胞死亡1配体;再生;长期随访;

相似文献

外文文献
中文文献
专利

1. Outcomes of long-term responders to anti-programmed death 1 and anti-programmed death ligand 1 when being rechallenged with the same anti-programmed death 1 and anti-programmed death ligand 1 at progression [J] . Bernard-Tessier A., Baldini C., Martin Patricia, European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2018,第期

机译：长期响应者的结果对反编程死亡1和反编程死亡配体1在进展中与相同的反编程死亡1和反编程死亡配体1进行重新启动时
2. Evaluation of objective response, disease control and progression-free survival as surrogate end-points for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials [J] . Nie Run-Cong, Chen Fo-Ping, Yuan Shu-Qiang, European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2019,第期

机译：评估客观反应，疾病控制和无进展生存作为反向死亡1和反编程死亡配体1次试验的整体存活的替代终点
3. Surrogate endpoints for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials of advanced melanoma [J] . Run-Cong Nie, Shu-Qiang Yuan, Yun Wang, Therapeutic advances in medical oncology. . 2020,第12期

机译：替代终点用于反编程死亡1和反编程死亡配体1先进心素瘤的试验
4. Molecular dynamics of the immune checkpoint Programmed Cell Death Protein I, PD-1: Conformational changes of the BC-loop upon binding of the ligand PD-L1 and the monoclonal antibody nivolumab [C] . Bernhard Roither, Chris Oostenbrink, Wolfgang Schreiner IEEE International Conference on Bioinformatics and Biomedicine . 2019

机译：免疫检查点的分子动力学程序性细胞死亡蛋白I，PD-1：配体PD-L1与单克隆抗体nivolumab结合后BC环的构象变化
5. Characterization of the Bax suppressor 14-3-3β/α as a possible anti-programmed cell death gene [D] . Clapp, Caitlin J. 2012

机译：Bax抑制剂14-3-3β/α作为可能的抗程序性细胞死亡基因的特征
6. Surrogate endpoints for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials of advanced melanoma [O] . Run-Cong Nie, Shu-Qiang Yuan, Yun Wang, 2020

机译：替代终点用于反编程死亡1和反编程死亡配体1先进心素瘤的试验
7. Surrogate endpoints for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials of advanced melanoma [O] . Run-Cong Nie, Shu-Qiang Yuan, Yun Wang, 2020

机译：替代终点用于反编程死亡1和反编程死亡配体1先进心素瘤的试验

Outcomes of long-term responders to anti-programmed death 1 and anti-programmed death ligand 1 when being rechallenged with the same anti-programmed death 1 and anti-programmed death ligand 1 at progression

摘要

著录项

相似文献

相关主题

期刊订阅